CRDF logo

Cardiff Oncology (CRDF) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 July 2004

Indexes:

Not included

Description:

Cardiff Oncology is a biotechnology company focused on developing new cancer treatments. They work on innovative therapies that target specific cancer cells, aiming to improve patient outcomes. Their research is centered on using advanced science to create effective and safer options for cancer patients.

Key Details

Price

$2.54

Annual Revenue

$488.00 K(+26.42% YoY)

Annual EPS

-$0.93(-4.49% YoY)

Annual ROE

-47.07%

Beta

1.70

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 07, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Feb 20, 2019

Analyst ratings

Recent major analysts updates

08 Nov '24 HC Wainwright & Co.
Buy
06 Sept '24 Craig-Hallum
Buy
06 May '24 HC Wainwright & Co.
Buy
06 Mar '24 HC Wainwright & Co.
Buy
01 Mar '24 Piper Sandler
Overweight
11 Aug '23 HC Wainwright & Co.
Buy
08 Aug '23 HC Wainwright & Co.
Buy
09 May '23 HC Wainwright & Co.
Buy
29 Mar '23 HC Wainwright & Co.
Buy
07 Mar '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
CRDF
zacks.com07 November 2024

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago.

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
CRDF
globenewswire.com30 October 2024

- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC -

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
CRDF
seekingalpha.com12 August 2024

Cardiff Oncology, Inc. results from the phase 2 CRDF-004 study, using onvansertib + Folfiri + bevacizumab for the treatment of patients with RAS-mutant mCRC, expected in the 2nd half of 2024. The global colorectal cancer market is expected to reach $30.09 billion by 2033; It said that about 50% of mCRC patients harbor the RAS mutation. A new phase 2 investigator-sponsored study, using onvansertib + Nalirifox for the treatment of 1st-line PDAC patients, will be deployed soon.

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
CRDF
seekingalpha.com10 August 2024

Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Andy Hsieh - William Blair Marc Frahm - TD Cowen Operator Welcome to the Cardiff Oncology Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
CRDF
zacks.com08 August 2024

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.

Cardiff Oncology to Present at the Jefferies Healthcare Conference
Cardiff Oncology to Present at the Jefferies Healthcare Conference
Cardiff Oncology to Present at the Jefferies Healthcare Conference
CRDF
globenewswire.com29 May 2024

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024.

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
CRDF
Seeking Alpha03 May 2024

Cardiff Oncology, Inc. (NASDAQ: CRDF) Q1 2024 Results Earnings Conference Call will take place on May 2, 2024 at 4:30 PM ET. The call will be led by Kiki Patel from Investor Relations at Gilmartin Group, with Mark Erlander as CEO and Jamie Levine as CFO. Conference Call Participants include Mark Frahm from TD Cowen, Joseph Catanzaro from Piper Sandler, and Andy Hsieh from William Blair. Welcome to the Cardiff Oncology First Quarter 2024 Financial Results and Business Update Conference Call. All participants are currently in a listen-only mode.

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
CRDF
Zacks Investment Research02 May 2024

Cardiff Oncology (CRDF) reported a quarterly loss of $0.22 per share, which was better than the expected loss of $0.25 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.25 per share in the same quarter last year.

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
CRDF
GlobeNewsWire25 April 2024

Management will host a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT.

Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
CRDF
Zacks Investment Research01 April 2024

Cardiff Oncology (CRDF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Cardiff Oncology?
  • What is the ticker symbol for Cardiff Oncology?
  • Does Cardiff Oncology pay dividends?
  • What sector is Cardiff Oncology in?
  • What industry is Cardiff Oncology in?
  • What country is Cardiff Oncology based in?
  • When did Cardiff Oncology go public?
  • Is Cardiff Oncology in the S&P 500?
  • Is Cardiff Oncology in the NASDAQ 100?
  • Is Cardiff Oncology in the Dow Jones?
  • When was Cardiff Oncology's last earnings report?
  • When does Cardiff Oncology report earnings?
  • Should I buy Cardiff Oncology stock now?

What is the primary business of Cardiff Oncology?

Cardiff Oncology is a biotechnology company focused on developing new cancer treatments. They work on innovative therapies that target specific cancer cells, aiming to improve patient outcomes. Their research is centered on using advanced science to create effective and safer options for cancer patients.

What is the ticker symbol for Cardiff Oncology?

The ticker symbol for Cardiff Oncology is NASDAQ:CRDF

Does Cardiff Oncology pay dividends?

No, Cardiff Oncology does not pay dividends

What sector is Cardiff Oncology in?

Cardiff Oncology is in the Healthcare sector

What industry is Cardiff Oncology in?

Cardiff Oncology is in the Biotechnology industry

What country is Cardiff Oncology based in?

Cardiff Oncology is headquartered in United States

When did Cardiff Oncology go public?

Cardiff Oncology's initial public offering (IPO) was on 27 July 2004

Is Cardiff Oncology in the S&P 500?

No, Cardiff Oncology is not included in the S&P 500 index

Is Cardiff Oncology in the NASDAQ 100?

No, Cardiff Oncology is not included in the NASDAQ 100 index

Is Cardiff Oncology in the Dow Jones?

No, Cardiff Oncology is not included in the Dow Jones index

When was Cardiff Oncology's last earnings report?

Cardiff Oncology's most recent earnings report was on 7 November 2024

When does Cardiff Oncology report earnings?

The next expected earnings date for Cardiff Oncology is 28 February 2025

Should I buy Cardiff Oncology stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions